DREAMM-7 study in R/R MM

Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, co-authored the DREAMM-7 study and shared updated efficacy data presented at ASH 2024.

DREAMM-7 is a phase 3, open-label, randomised trial comparing two triplets for R/R MM: belantamab mafodotin, bortezomib and dexamethasone (BVd) vs. daratumumab, bortezomib and dexamethasone (DVd).

BVd demonstrated impressive results, outperforming DVd across all predefined groups, despite not yet reaching OS endpoints. It showed strong overall response rates, excellent MRD negativity rates, and good tolerability.

These findings suggest BVd could become a new standard of care for early relapsed MM, particularly from the second line. The data may also redefine treatment sequencing, especially for lenalidomide-refractory patients or those relapsing during lenalidomide maintenance or after DRd in transplant-ineligible cases.

This combination marks a potential game changer in the evolving treatment landscape for relapsed/refractory multiple myeloma.